title: Folate-based radiotracers for PET imaging--update and perspectives.
abstract: The folate receptor (FR) is expressed in many tumor types, among those ovarian and lung cancer. Due to the high FR affinity of folic acid, it has been used for targeting of FR-positive tumors, allowing specific delivery of attached probes to the malignant tissue. Therefore, nuclear imaging of FR-positive cancer is of clinical interest for selecting patients who could benefit from innovative therapy concepts based on FR-targeting. Positron emission computed tomography (PET) has become an established technique in clinical routine because it provides an increased spatial resolution and higher sensitivity compared to single photon emission computed tomography (SPECT). Therefore, it is of critical importance to develop folate radiotracers suitable for PET imaging. This review article updates on the design, preparation and pre-clinical investigation of folate derivatives for radiolabeling with radioisotopes for PET. Among those the most relevant radionuclides so far are fluorine-18 (t(1/2): 110 min, E(av) β⁺: 250 keV) and gallium-68 (t(1/2): 68 min, E(av) β⁺: 830 keV). Recent results obtained with new PET isotopes such as terbium-152 (t(1/2): 17.5 h, Eβ⁺: 470 keV) or scandium-44 (t(1/2): 3.97 h, (Eav) β⁺: 632 keV) are also presented and discussed. Current endeavors for clinical implementation of PET agents open new perspectives for identification of FR-positive malignancies in patients.
authors: Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI 5232, Switzerland. cristina.mueller@psi.ch
authors: Cristina
authors: C
authors: Müller
mesh_terms: D000818:Animals; D005462:Fluorine Radioisotopes / Q000737:chemistry / Q000494:pharmacology; D058975:Folate Receptor 1 / Q000819:agonists / Q000378:metabolism; D005492:Folic Acid / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D005709:Gallium Isotopes / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D009363:Neoplasm Proteins / Q000819:agonists / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000378:metabolism; D049268:Positron-Emission Tomography / Q000379:methods*; D011859:Radiography; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D013725:Terbium / Q000737:chemistry / Q000494:pharmacology
chemical_list: D005462:Fluorine Radioisotopes; D058975:Folate Receptor 1; D005709:Gallium Isotopes; D009363:Neoplasm Proteins; D019275:Radiopharmaceuticals; D013725:Terbium; D005492:Folic Acid
references: Arthritis Rheum. 1997 Feb;40(2):217-25
references: 9041933
references: Med Phys. 1997 Feb;24(2):317-26
references: 9048374
references: J Nucl Med. 2013 Dec;54(12):2168-74
references: 24198390
references: Am J Pathol. 1993 Feb;142(2):557-67
references: 8434649
references: Cancer. 2003 Apr 15;97(8 Suppl):2056-63
references: 12673697
references: Mol Imaging Biol. 2013 Feb;15(1):79-86
references: 22565849
references: Mod Pathol. 2011 Sep;24(9):1221-8
references: 21572402
references: J Nucl Med. 2011 Jan;52(1):1-4
references: 21149477
references: J Thorac Oncol. 2012 Oct;7(10):1618-21
references: 22982661
references: Arthritis Res Ther. 2011 Apr 04;13(2):R56
references: 21463515
references: J Org Chem. 2002 May 3;67(9):3057-64
references: 11975567
references: Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):938-46
references: 19183997
references: Appl Radiat Isot. 2012 Dec;70(12):2669-76
references: 23037921
references: J Nucl Med. 2007 Oct;48(10):1741-8
references: 17873136
references: Biochemistry. 1994 Feb 8;33(5):1209-15
references: 8110752
references: Angew Chem Int Ed Engl. 2008;47(47):8998-9033
references: 18988199
references: Biochemistry. 1995 Apr 25;34(16):5660-5
references: 7727426
references: Phys Med Biol. 2004 May 21;49(10):2069-81
references: 15214542
references: Bioconjug Chem. 2008 Dec;19(12):2462-70
references: 19053298
references: Pharm Res. 2009 Jun;26(6):1315-23
references: 19189203
references: Arthritis Res Ther. 2012 May 02;14(3):R106
references: 22551402
references: Bioconjug Chem. 2009 Oct 21;20(10):1940-9
references: 19803478
references: Nucl Med Biol. 2002 Nov;29(8):817-23
references: 12453591
references: J Nucl Med. 2008 Jun;49(6):899-906
references: 18483093
references: J Nucl Med. 2003 May;44(5):700-7
references: 12732670
references: Annu Rev Nutr. 1996;16:501-21
references: 8839936
references: Cancer Res. 2003 Jul 1;63(13):3612-8
references: 12839949
references: Arthritis Rheum. 2002 Jul;46(7):1947-55
references: 12124880
references: J Nucl Med. 2012 Nov;53(11):1686-92
references: 22984220
references: Mol Pharm. 2012 May 7;9(5):1136-45
references: 22497506
references: Contrast Media Mol Imaging. 2008 Mar-Apr;3(2):67-77
references: 18383558
references: Mol Pharm. 2009 Jul-Aug;6(4):1228-36
references: 19374407
references: J Nucl Med. 2010 Sep;51(9):1349-56
references: 20720050
references: Acc Chem Res. 2008 Jan;41(1):120-9
references: 17655275
references: J Drug Target. 1999;7(3):157-69
references: 10680972
references: Curr Opin Chem Biol. 2009 Jun;13(3):256-62
references: 19419901
references: Eur J Oral Sci. 2009 Feb;117(1):90-1
references: 19196324
references: Curr Pharm Des. 2012;18(8):1058-83
references: 22272825
references: Recent Results Cancer Res. 2013;194:257-67
references: 22918763
references: J Am Soc Nephrol. 2005 Mar;16(3):608-15
references: 15703271
references: Radiol Clin North Am. 2009 Jan;47(1):147-60
references: 19195540
references: J Nucl Med. 2013 Jan;54(1):124-31
references: 23236020
references: Int J Cancer. 1998 Apr 17;79(2):121-6
references: 9583724
references: Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93
references: 17225119
references: Arthritis Res. 2000;2(3):189-202
references: 11094428
references: J Nucl Med. 2006 Jul;47(7):1153-60
references: 16818950
references: Carbohydr Res. 2009 Apr 21;344(6):753-61
references: 19303067
references: Nucl Med Biol. 2011 Oct;38(7):1019-28
references: 21982573
references: Mol Pharm. 2012 May 7;9(5):1435-40
references: 22468849
references: J Nucl Med. 2008 Apr;49(4):623-9
references: 18344429
references: Arthritis Rheum. 2011 Jul;63(7):1898-907
references: 21437875
references: Gene. 2000 Nov 27;258(1-2):117-25
references: 11111049
references: J Nucl Med. 2008 Feb;49(2):310-7
references: 18199624
references: Bioconjug Chem. 2013 Feb 20;24(2):205-14
references: 23273015
references: J Am Chem Soc. 2005 May 25;127(20):7421-6
references: 15898791
references: Curr Pharm Des. 2012;18(18):2657-69
references: 22512443
references: Bioconjug Chem. 2012 Apr 18;23(4):805-13
references: 22372827
references: J Nucl Med. 2010 May;51(5):768-74
references: 20395331
references: J Nucl Med. 2012 Dec;53(12):1951-9
references: 23139086
references: Cancer Res. 1992 Jun 15;52(12):3396-401
references: 1596899
references: Nucl Med Biol. 1999 Jan;26(1):23-5
references: 10096497
references: Angew Chem Int Ed Engl. 2002 Jul 15;41(14):2596-9
references: 12203546
references: Kidney Int. 1992 Jan;41(1):50-5
references: 1593862
references: Curr Radiopharm. 2012 Jul;5(3):187-201
references: 22642388
references: Anal Biochem. 2005 Mar 15;338(2):284-93
references: 15745749
references: Cancer Res. 1992 Dec 1;52(23):6708-11
references: 1330299
references: J Nucl Med. 2006 Dec;47(12):2057-64
references: 17138750
references: Ann Surg Oncol. 2008 Mar;15(3):889-99
references: 18181001
references: Mol Pharm. 2010 Apr 5;7(2):597-604
references: 20199053
references: Nucl Med Biol. 2012 Aug;39(6):864-70
references: 22445744
references: Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1007-16
references: 16763819
references: Am J Physiol Cell Physiol. 2004 Aug;287(2):C517-26
references: 15102609
references: Angew Chem Int Ed Engl. 2008;47(17):3196-201
references: 18366035
references: Arthritis Res Ther. 2011 Apr 08;13(2):R59
references: 21477314
references: Bioorg Med Chem Lett. 2012 Jan 1;22(1):709-12
references: 22100311
references: Nucl Med Biol. 2011 Aug;38(6):917-24
references: 21843788
references: Int J Cancer. 2008 Oct 1;123(7):1699-703
references: 18646191
references: J Nucl Med. 2010 Nov;51(11):1756-62
references: 20956469
references: Mol Pharmacol. 1995 Sep;48(3):459-71
references: 7565626
references: Lancet Oncol. 2001 May;2(5):298-306
references: 11905785
references: Angew Chem Int Ed Engl. 2010;49(5):976-9
references: 20029856
references: Int J Cancer. 2007 Sep 1;121(5):938-42
references: 17487842
references: J Inorg Biochem. 2011 Feb;105(2):313-20
references: 21194633
references: Appl Radiat Isot. 2012 Aug;70(8):1526-30
references: 22728844
references: Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):108-19
references: 20799032
references: J Nucl Med. 1999 Sep;40(9):1563-9
references: 10492380
references: J Nucl Med. 2007 Apr;48(4):508-18
references: 17401086
references: Nucl Med Biol. 2011 Jul;38(5):715-23
references: 21718947
references: Cancer Biother Radiopharm. 1998 Jun;13(3):177-84
references: 10850353
references: Bioorg Med Chem Lett. 2011 Apr 1;21(7):2025-9
references: 21377880
references: Adv Drug Deliv Rev. 2004 Apr 29;56(8):1205-17
references: 15094216
references: Biochemistry. 1989 Oct 3;28(20):8249-54
references: 2605182
references: J Nucl Med. 1996 Jun;37(6):1003-8
references: 8683292
references: Nucl Med Biol. 2003 Oct;30(7):725-31
references: 14499330
references: Blood. 2009 Jan 8;113(2):438-46
references: 18952896
references: Bioconjug Chem. 1997 Sep-Oct;8(5):673-9
references: 9327130
references: Bioconjug Chem. 2008 Aug;19(8):1689-95
references: 18646835
references: Appl Radiat Isot. 2001 Jan;54(1):53-8
references: 11144253
references: Adv Drug Deliv Rev. 2004 Apr 29;56(8):1143-60
references: 15094212